← All trials
NCT05166837
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 10, 2022
- Primary completion
- Jul 31, 2022
- Completion date
- Jul 31, 2022
- First posted
- Dec 22, 2021
- Last posted
- Jan 13, 2022
- Enrollment
- 52
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Staidson (Beijing) Biopharmaceuticals Co., LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.